Patterns of cytomegalovirus retinitis in immunocompromised patients treated with 9-(2-hydroxy-1-(hydroxymethyl)ethoxymethyl) guanine (ganciclovir). 1991

D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
Cattedre di Ematologia, Università degli Studi G. D'Annunzio, Chieti, Italy.

Five immunocompromised patients, four with AIDS and one who had undergone bone marrow transplantation, showing ocular signs of cytomegalovirus retinitis, were treated with 9-(2-hydroxy-1-(hydroxymethyl)ethoxymethyl) guanine (Ganciclovir), given intravenously at the dose of 5 mg/kg twice daily for a period ranging from 10 to 20 days. At the end of the treatment, in 4 of 5 patients, the ophthalmoscopic picture had improved, with reduced exudation and an arrest in the progression of retinal necrosis, the pattern clearly indicating a trend towards organization and scarring. Complete resolution of the retinitis without subsequent relapse was observed only in the bone marrow transplant patient, who recovered immunologically, whereas improvement of the eye involvement was only transient in the three AIDS patients.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D008297 Male Males
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012173 Retinitis Inflammation of the RETINA. It is rarely limited to the retina, but is commonly associated with diseases of the choroid (CHORIORETINITIS) and of the OPTIC DISK (neuroretinitis). Neuroretinitis

Related Publications

D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
July 1988, The British journal of ophthalmology,
D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
September 1985, Annals of internal medicine,
D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
April 1988, The British journal of ophthalmology,
D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
September 1985, Annals of internal medicine,
D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
August 1986, Annals of internal medicine,
D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
June 1986, Lancet (London, England),
D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
February 1988, Antimicrobial agents and chemotherapy,
D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
October 1988, Transplantation,
D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
December 1986, Archives of ophthalmology (Chicago, Ill. : 1960),
D D'Antonio, and A Iacone, and G Fioritoni, and M Dell'Isola, and L Mastropasqua, and L Lobefalo, and G C De Nicola, and V Paolone, and P Di Gregorio, and A Recchia
October 1987, Annals of ophthalmology,
Copied contents to your clipboard!